These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. Patel P; Salapatek AM Expert Rev Vaccines; 2006 Oct; 5(5):617-29. PubMed ID: 17181436 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. Patel P; Holdich T; Fischer von Weikersthal-Drachenberg KJ; Huber B J Allergy Clin Immunol; 2014 Jan; 133(1):121-9.e1-2. PubMed ID: 23870670 [TBL] [Abstract][Full Text] [Related]
5. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Drachenberg KJ; Wheeler AW; Stuebner P; Horak F Allergy; 2001 Jun; 56(6):498-505. PubMed ID: 11421893 [TBL] [Abstract][Full Text] [Related]
6. Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL). Hopkins M; Lees BG; Richardson DG; Woroniecki SR; Wheeler AW Allergol Immunopathol (Madr); 2001; 29(6):245-54. PubMed ID: 11834183 [TBL] [Abstract][Full Text] [Related]
7. Long-term effect of monophosphoryl lipid A adjuvanted specific immunotherapy in patients with grass pollen allergy. Zielen S; Gabrielpillai J; Herrmann E; Schulze J; Schubert R; Rosewich M Immunotherapy; 2018 Jun; 10(7):529-536. PubMed ID: 29562801 [TBL] [Abstract][Full Text] [Related]
8. Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis. Rosewich M; Lee D; Zielen S Hum Vaccin Immunother; 2013 Jul; 9(7):1523-31. PubMed ID: 23584250 [TBL] [Abstract][Full Text] [Related]
9. Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy. Baldrick P; Richardson D; Woroniecki SR; Lees B J Appl Toxicol; 2007; 27(4):399-409. PubMed ID: 17299813 [TBL] [Abstract][Full Text] [Related]
10. Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet. Nelson H; Lehmann L; Blaiss MS Curr Med Res Opin; 2012 Jun; 28(6):1043-51. PubMed ID: 22502864 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32. Niederberger V; Neubauer A; Gevaert P; Zidarn M; Worm M; Aberer W; Malling HJ; Pfaar O; Klimek L; Pfützner W; Ring J; Darsow U; Novak N; Gerth van Wijk R; Eckl-Dorna J; Focke-Tejkl M; Weber M; Müller HH; Klinger J; Stolz F; Breit N; Henning R; Valenta R J Allergy Clin Immunol; 2018 Aug; 142(2):497-509.e9. PubMed ID: 29361332 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. Frew AJ; Powell RJ; Corrigan CJ; Durham SR; J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Drachenberg KJ; Heinzkill M; Urban E; Woroniecki SR Allergol Immunopathol (Madr); 2003; 31(5):270-7. PubMed ID: 14572416 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Six Different Allergen Extracts for Subcutaneous Specific Immunotherapy in Children: An Open-Labelled, Prospective, Controlled Observational Trial. Kopp MV; König IR; Friedrichs F; Umpfenbach HU; Niggemann B; Millner-Uhlemann M Int Arch Allergy Immunol; 2019; 180(4):284-290. PubMed ID: 31665735 [TBL] [Abstract][Full Text] [Related]
17. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937 [TBL] [Abstract][Full Text] [Related]
18. Sublingual immunotherapy: allergen specific or placebo effect? Kette F; Smith W J Allergy Clin Immunol; 2011 Aug; 128(2):430; author reply 430-2. PubMed ID: 21665261 [No Abstract] [Full Text] [Related]
19. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis. Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092 [TBL] [Abstract][Full Text] [Related]